Neurosoft Bioelectronics Secures $7.5M Seed Funding Led by Skybound Venture Capital

Why It Matters

The funding validates a scalable, less invasive BCI approach that could unlock massive neural datasets, accelerating both clinical therapies and next‑generation brain‑interface technologies.

Key Takeaways

• Raised $7.5M seed round, total funding exceeds $20M
• Soft, stretchable electrodes enable non‑penetrating cortical access
• 10 patients enrolled in two clinical trials across US and Europe
• Goal: large‑scale neural data platform for cortical foundation models
• Funding will drive minimally invasive deployment and US commercialization

Pulse Analysis

The brain‑computer interface (BCI) market has long been hampered by invasive hardware that risks tissue damage and limits coverage. Neurosoft Bioelectronics tackles this bottleneck with a soft, stretchable electrode array that conforms to the brain’s surface, offering full‑cortex access without penetration. By sidestepping the surgical complexities of traditional probes, the company positions itself to attract both research institutions and medical centers seeking safer, repeatable neural recordings.

Beyond the hardware, Neurosoft’s ambition centers on a data‑centric strategy. Collecting high‑fidelity signals from a broad cortical area enables the creation of foundation models—large‑scale neural representations that can improve algorithmic decoding for both invasive and non‑invasive BCIs. The ongoing trials at UTHealth Houston and UMC Utrecht, involving 10 patients and a 64‑channel epilepsy‑guidance study, provide early proof points that the platform can deliver clinically relevant insights while maintaining patient safety.

The $7.5 million seed injection, led by Skybound Venture Capital, signals strong investor confidence in this minimally invasive paradigm. With total funding now surpassing $20 million, Neurosoft can accelerate regulatory pathways, scale manufacturing, and launch its first commercial product in the United States. If successful, the company could reshape the BCI landscape, driving down costs, expanding therapeutic applications, and feeding a virtuous cycle of data‑driven innovation for the broader neurotechnology ecosystem.

Deal Summary

Swiss neurotechnology firm Neurosoft Bioelectronics raised $7.5 million in a seed round led by Skybound Venture Capital, with participation from Protocol Labs, IAG Capital Partners and Connecticut Innovations. The funding will support the development of its minimally invasive brain‑computer interface platform and advance clinical trials toward U.S. commercialization.